Literature DB >> 19889988

A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection.

Hulya Karatas1, Yesim Aktas, Yasemin Gursoy-Ozdemir, Ebru Bodur, Muge Yemisci, Secil Caban, Atay Vural, Onur Pinarbasli, Yilmaz Capan, Eduardo Fernandez-Megia, Ramon Novoa-Carballal, Ricardo Riguera, Karine Andrieux, Patrick Couvreur, Turgay Dalkara.   

Abstract

Caspases play an important role as mediators of cell death in acute and chronic neurological disorders. Although peptide inhibitors of caspases provide neuroprotection, they have to be administered intracerebroventricularly because they cannot cross the blood-brain barrier (BBB). Herein, we present a nanocarrier system that can transfer chitosan nanospheres loaded with N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone (Z-DEVD-FMK), a relatively specific caspase-3 inhibitor, across BBB. Caspase-3 was chosen as a pharmacological target because of its central role in cell death. Polyethylene glycol-coated nanospheres were conjugated to an anti-mouse transferrin receptor monoclonal antibody (TfRMAb) that selectively recognizes the TfR type 1 on the cerebral vasculature. We demonstrate with intravital microscopy that this nanomedicine is rapidly transported across the BBB without being measurably taken up by liver and spleen. Pre- or post-treatment (2 h) with intravenously injected Z-DEVD-FMK-loaded nanospheres dose dependently decreased the infarct volume, neurological deficit, and ischemia-induced caspase-3 activity in mice subjected to 2 h of MCA occlusion and 24 h of reperfusion, suggesting that they released an amount of peptide sufficient to inhibit caspase activity. Similarly, nanospheres inhibited physiological caspase-3 activity during development in the neonatal mouse cerebellum on postnatal day 17 after closure of the BBB. Neither nanospheres functionalized with TfRMAb but not loaded with Z-DEVD-FMK nor nanospheres lacking TfRMAb but loaded with Z-DEVD-FMK had any effect on either paradigm, suggesting that inhibition of caspase activity and subsequent neuroprotection were due to efficient penetration of the peptide into brain. Thus, chitosan nanospheres open new and exciting opportunities for brain delivery of biologically active peptides that are useful for the treatment of CNS disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889988      PMCID: PMC6666719          DOI: 10.1523/JNEUROSCI.4246-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

Review 1.  Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Anthony J McGoron
Journal:  Appl Biochem Biotechnol       Date:  2011-09-27       Impact factor: 2.926

2.  Identification of novel specific allosteric modulators of the glycine receptor using phage display.

Authors:  Megan E Tipps; Jessica E Lawshe; Andrew D Ellington; S John Mihic
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

Review 3.  The executioners sing a new song: killer caspases activate microglia.

Authors:  J L Venero; M A Burguillos; P Brundin; B Joseph
Journal:  Cell Death Differ       Date:  2011-08-12       Impact factor: 15.828

Review 4.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

Review 5.  Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

Authors:  Thuy Trang Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Chitosan nanoparticles are efficient carriers for delivering biodegradable drugs to neuronal cells.

Authors:  M Malatesta; V Galimberti; B Cisterna; M Costanzo; M Biggiogera; C Zancanaro
Journal:  Histochem Cell Biol       Date:  2013-12-20       Impact factor: 4.304

Review 7.  Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models.

Authors:  Luigi Titomanlio; David Fernández-López; Lucilla Manganozzi; Raffaella Moretti; Zinaida S Vexler; Pierre Gressens
Journal:  Pediatr Neurol       Date:  2015-01-31       Impact factor: 3.372

Review 8.  Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases.

Authors:  Afshin Saffari; Stefan Kölker; Georg F Hoffmann; Darius Ebrahimi-Fakhari
Journal:  J Inherit Metab Dis       Date:  2017-05-05       Impact factor: 4.982

Review 9.  Polymeric nanoparticles for drug delivery to the central nervous system.

Authors:  Toral Patel; Jiangbing Zhou; Joseph M Piepmeier; W Mark Saltzman
Journal:  Adv Drug Deliv Rev       Date:  2011-12-20       Impact factor: 15.470

10.  Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection.

Authors:  Muge Yemisci; Secil Caban; Yasemin Gursoy-Ozdemir; Sevda Lule; Ramon Novoa-Carballal; Ricardo Riguera; Eduardo Fernandez-Megia; Karine Andrieux; Partick Couvreur; Yilmaz Capan; Turgay Dalkara
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.